CL2017002031A1 - Formulación en polvo nasal para el tratamiento de hipoglicemia - Google Patents
Formulación en polvo nasal para el tratamiento de hipoglicemiaInfo
- Publication number
- CL2017002031A1 CL2017002031A1 CL2017002031A CL2017002031A CL2017002031A1 CL 2017002031 A1 CL2017002031 A1 CL 2017002031A1 CL 2017002031 A CL2017002031 A CL 2017002031A CL 2017002031 A CL2017002031 A CL 2017002031A CL 2017002031 A1 CL2017002031 A1 CL 2017002031A1
- Authority
- CL
- Chile
- Prior art keywords
- powder formulation
- treatment
- hypoglycemia
- nasal powder
- nasal
- Prior art date
Links
- 238000009472 formulation Methods 0.000 title abstract 4
- 239000000203 mixture Substances 0.000 title abstract 4
- 208000013016 Hypoglycemia Diseases 0.000 title abstract 2
- 230000002218 hypoglycaemic effect Effects 0.000 title abstract 2
- 229940052404 nasal powder Drugs 0.000 title 1
- MASNOZXLGMXCHN-ZLPAWPGGSA-N glucagon Chemical compound C([C@@H](C(=O)N[C@H](C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(O)=O)C(C)C)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](C)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CO)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CO)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](N)CC=1NC=NC=1)[C@@H](C)O)[C@@H](C)O)C1=CC=CC=C1 MASNOZXLGMXCHN-ZLPAWPGGSA-N 0.000 abstract 2
- 238000000034 method Methods 0.000 abstract 2
- 239000000843 powder Substances 0.000 abstract 2
- 102000051325 Glucagon Human genes 0.000 abstract 1
- 108060003199 Glucagon Proteins 0.000 abstract 1
- 229960004666 glucagon Drugs 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
- A61K31/716—Glucans
- A61K31/724—Cyclodextrins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
- A61K38/26—Glucagons
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/12—Carboxylic acids; Salts or anhydrides thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/24—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing atoms other than carbon, hydrogen, oxygen, halogen, nitrogen or sulfur, e.g. cyclomethicone or phospholipids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
- A61K47/40—Cyclodextrins; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0043—Nose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
- A61K9/145—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
- A61K9/146—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic macromolecular compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M15/00—Inhalators
- A61M15/0065—Inhalators with dosage or measuring devices
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M11/00—Sprayers or atomisers specially adapted for therapeutic purposes
- A61M11/02—Sprayers or atomisers specially adapted for therapeutic purposes operated by air or other gas pressure applied to the liquid or other product to be sprayed or atomised
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M15/00—Inhalators
- A61M15/0028—Inhalators using prepacked dosages, one for each application, e.g. capsules to be perforated or broken-up
- A61M15/003—Inhalators using prepacked dosages, one for each application, e.g. capsules to be perforated or broken-up using capsules, e.g. to be perforated or broken-up
- A61M15/0043—Non-destructive separation of the package, e.g. peeling
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M15/00—Inhalators
- A61M15/08—Inhaling devices inserted into the nose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M2202/00—Special media to be introduced, removed or treated
- A61M2202/06—Solids
- A61M2202/064—Powder
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M2205/00—General characteristics of the apparatus
- A61M2205/07—General characteristics of the apparatus having air pumping means
- A61M2205/071—General characteristics of the apparatus having air pumping means hand operated
- A61M2205/073—Syringe, piston type
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Molecular Biology (AREA)
- Otolaryngology (AREA)
- Hematology (AREA)
- Endocrinology (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Biophysics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Immunology (AREA)
- Gastroenterology & Hepatology (AREA)
- Zoology (AREA)
- Diabetes (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pulmonology (AREA)
- Heart & Thoracic Surgery (AREA)
- Biomedical Technology (AREA)
- Anesthesiology (AREA)
- Obesity (AREA)
- Inorganic Chemistry (AREA)
- Emergency Medicine (AREA)
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Abstract
<p>LA PRESENTE INVENCIÓN SE REFIERE A UNA FORMULACIÓN EN POLVO QUE CONTIENE GLUCAGÓN O UN ANÁLOGO DE GLUCAGÓN PARA ADMINISTRACIÓN NASAL, ÚTIL EN EL TRATAMIENTO DE HIPOGLICEMIA, Y EN PARTICULAR EL TRATAMIENTO DE HIPOGLICEMIA SEVERA. LA PRESENTE INVENCIÓN TAMBIÉN PROPORCIONA UN MÉTODO PARA ELABORAR ESTA FORMULACIÓN EN POLVO, Y A DISPOSITIVOS Y MÉTODOS PARA USAR LA FORMULACIÓN EN POLVO.</p>
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201562117031P | 2015-02-17 | 2015-02-17 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CL2017002031A1 true CL2017002031A1 (es) | 2018-03-23 |
Family
ID=55538593
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CL2017002031A CL2017002031A1 (es) | 2015-02-17 | 2017-08-08 | Formulación en polvo nasal para el tratamiento de hipoglicemia |
Country Status (41)
Families Citing this family (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SG11201705640PA (en) * | 2015-02-17 | 2017-08-30 | Lilly Co Eli | Nasal powder formulation for treatment of hypoglycemia |
| US11013873B2 (en) * | 2017-01-06 | 2021-05-25 | HealthPartners Institite | Methods for treating patients with impaired awareness of hypoglycemia |
| ES2894629T3 (es) | 2017-06-16 | 2022-02-15 | Zealand Pharma As | Pautas posológicas para la administración de análogos del péptido 2 similar al glucagón (GLP-2) |
| US11844859B2 (en) | 2017-08-20 | 2023-12-19 | Nasus Pharma Ltd. | Dry powder compositions for intranasal delivery |
| JP7334145B2 (ja) | 2017-08-20 | 2023-08-28 | ネイサス ファーマ リミテッド | 鼻腔内送達用乾燥粉末組成物 |
| AU2018335869B2 (en) * | 2017-09-21 | 2024-06-13 | Avanti Polar Lipids, Llc | Novel therapies for treating and preventing chronic rhinosinusitis |
| TWI771669B (zh) * | 2019-04-26 | 2022-07-21 | 美商美國禮來大藥廠 | 製備穩定胜肽調配物之方法 |
| US10653690B1 (en) | 2019-07-09 | 2020-05-19 | Orexo Ab | Pharmaceutical composition for nasal delivery |
| US10729687B1 (en) | 2019-07-09 | 2020-08-04 | Orexo Ab | Pharmaceutical composition for nasal delivery |
| HRP20251267T1 (hr) | 2020-03-16 | 2025-12-05 | Zealand Pharma A/S | Tekuće formulacije glukagonskih analoga |
| PE20230382A1 (es) | 2020-05-18 | 2023-03-06 | Orexo Ab | Nueva composicion farmaceutica para administracion de farmacos |
| IL313016A (en) | 2021-11-25 | 2024-07-01 | Orexo Ab | A pharmaceutical preparation that includes adrenaline |
| GB202117016D0 (en) | 2021-11-25 | 2022-01-12 | Orexo Ab | New pharmaceutical device |
| CN119454909B (zh) * | 2025-01-13 | 2025-04-08 | 上海世领制药有限公司 | 经鼻粘膜给药的胰高血糖素样肽-1受体激动剂的制剂组合物、制备方法、用途及鼻施用器 |
Family Cites Families (37)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPS58189118A (ja) * | 1982-04-30 | 1983-11-04 | Takeda Chem Ind Ltd | 経鼻投与製剤 |
| NZ222907A (en) | 1986-12-16 | 1990-08-28 | Novo Industri As | Preparation for intranasal administration containing a phospholipid absorption enhancing system |
| US5179079A (en) | 1986-12-16 | 1993-01-12 | Novo Nordisk A/S | Nasal formulation and intranasal administration therewith |
| US5059587A (en) | 1987-08-03 | 1991-10-22 | Toyo Jozo Company, Ltd. | Physiologically active peptide composition for nasal administration |
| EP0308181A1 (en) * | 1987-09-14 | 1989-03-22 | Novo Nordisk A/S | Trans-mucosal delivery formulations and a method for preparation thereof |
| DK49791D0 (da) * | 1991-03-20 | 1991-03-20 | Novo Nordisk As | Nasalt pulverpraeparat |
| DE19518810A1 (de) | 1995-05-26 | 1996-11-28 | Bayer Ag | Nasal-Applikator |
| JP3098401B2 (ja) | 1995-07-12 | 2000-10-16 | 株式会社エルティーティー研究所 | 経鼻投与用製剤 |
| JPH11292787A (ja) | 1995-08-15 | 1999-10-26 | Asahi Chem Ind Co Ltd | 生理活性ペプチドを含有する経粘膜投与製剤 |
| DE69913113T2 (de) | 1998-03-10 | 2004-08-26 | Valois S.A.S. | Behälter, verfahren zur befüllung dieses behälter und abgabevorrichtung für das im behälter enthaltene pulver |
| DE69918070T2 (de) | 1998-03-13 | 2005-08-25 | Novo Nordisk A/S | Stabilisierte, wässrige Glukagonlösungen, enthaltend Detergenzien |
| WO1999047160A1 (en) | 1998-03-13 | 1999-09-23 | Novo Nordisk A/S | Stabilized aqueous peptide solutions |
| FR2817847B1 (fr) | 2000-12-08 | 2003-03-28 | Tebro | Dispositif de distribution de produit fluide ou pulverulent |
| US6522144B2 (en) | 2000-12-22 | 2003-02-18 | Ge Medical Systems Global Technology Company, Llc | RF shielding method and apparatus for an open MRI system |
| AU2003212912A1 (en) | 2002-02-04 | 2003-09-02 | Millipore Corporation | Process for removing protein aggregates and virus from a protein solution |
| KR101036150B1 (ko) | 2003-10-09 | 2011-05-23 | 가부시키가이샤 바이오악티스 | 비강용 분말 약제 투약 장치 |
| US20080318837A1 (en) | 2003-12-26 | 2008-12-25 | Nastech Pharmaceutical Company Inc. | Pharmaceutical Formation For Increased Epithelial Permeability of Glucose-Regulating Peptide |
| US20060074025A1 (en) * | 2003-12-26 | 2006-04-06 | Nastech Pharmaceutical Company Inc. | Therapeutic formulations for transmucosal administration that increase glucagon-like peptide-1 bioavailability |
| US8268791B2 (en) | 2004-08-25 | 2012-09-18 | Aegis Therapeutics, Llc. | Alkylglycoside compositions for drug administration |
| MX2008007075A (es) | 2005-12-02 | 2008-11-12 | Mdrna Inc | Formulacion farmaceutica para incrementar la permeabilidad epitelial por peptido regulador de glucosa. |
| EP2158214B1 (en) | 2007-06-15 | 2011-08-17 | Zealand Pharma A/S | Glucagon analogues |
| MA32970B1 (fr) | 2008-12-15 | 2012-01-02 | Zealand Pharma As | Analogues du glucagon |
| BRPI0823377A2 (pt) | 2008-12-15 | 2016-09-27 | Zealand Pharma As | análogos de glucagon |
| JP5635530B2 (ja) | 2008-12-15 | 2014-12-03 | ジーランド ファーマ アクティーゼルスカブ | グルカゴン類似体 |
| JP6054742B2 (ja) | 2009-07-13 | 2016-12-27 | ジーランド ファーマ アクティーゼルスカブ | アシル化グルカゴン類似体 |
| GB2472327B (en) | 2009-07-31 | 2013-03-13 | Shin Nippon Biomedical Lab Ltd | Intranasal granisetron and nasal applicator |
| US9610329B2 (en) * | 2009-10-22 | 2017-04-04 | Albireo Pharma, Inc. | Stabilized glucagon solutions |
| CN102933598A (zh) * | 2010-03-26 | 2013-02-13 | 诺沃—诺迪斯克有限公司 | 新型胰高血糖素类似物 |
| UY33462A (es) | 2010-06-23 | 2012-01-31 | Zealand Pharma As | Analogos de glucagon |
| US9169310B2 (en) | 2010-06-24 | 2015-10-27 | Zealand Pharma A/S | Glucagon analogues |
| WO2012166061A2 (es) | 2011-05-27 | 2012-12-06 | COLLAZO HANDAL, José Schafik | Bebida para la reposición rápida de iones calcio en el torrente sanguíneo |
| US8729017B2 (en) | 2011-06-22 | 2014-05-20 | Indiana University Research And Technology Corporation | Glucagon/GLP-1 receptor co-agonists |
| SG11201403377QA (en) | 2011-12-23 | 2014-07-30 | Zealand Pharma As | Glucagon analogues |
| WO2014004400A2 (en) | 2012-06-28 | 2014-01-03 | The Governt. Of The Usa As Represented By The Secretary Of The Department Of Health & Human Services | Nasal dry powder delivery system for vaccines and other treatment agents |
| FI124134B (en) | 2012-07-02 | 2014-03-31 | One Way Sport Oy | Binding between a ski and a ski boot |
| TWI608013B (zh) | 2012-09-17 | 2017-12-11 | 西蘭製藥公司 | 升糖素類似物 |
| SG11201705640PA (en) * | 2015-02-17 | 2017-08-30 | Lilly Co Eli | Nasal powder formulation for treatment of hypoglycemia |
-
2016
- 2016-02-16 SG SG11201705640PA patent/SG11201705640PA/en unknown
- 2016-02-16 PL PL16710352.2T patent/PL3258919T5/pl unknown
- 2016-02-16 CA CA2975562A patent/CA2975562C/en active Active
- 2016-02-16 MA MA41547A patent/MA41547B1/fr unknown
- 2016-02-16 EP EP20151175.5A patent/EP3673900B1/en active Active
- 2016-02-16 MA MA052252A patent/MA52252A/fr unknown
- 2016-02-16 CN CN201680010778.8A patent/CN107278154B/zh active Active
- 2016-02-16 RS RS20200145A patent/RS59918B2/sr unknown
- 2016-02-16 SI SI201630611T patent/SI3258919T2/sl unknown
- 2016-02-16 US US15/545,332 patent/US10213487B2/en active Active
- 2016-02-16 MX MX2017010572A patent/MX376200B/es active IP Right Grant
- 2016-02-16 WO PCT/US2016/018003 patent/WO2016133863A1/en not_active Ceased
- 2016-02-16 TN TNP/2017/000349A patent/TN2017000349A1/en unknown
- 2016-02-16 MD MDE20180006T patent/MD3258919T3/ro unknown
- 2016-02-16 MA MA052253A patent/MA52253A/fr unknown
- 2016-02-16 DK DK16710352.2T patent/DK3258919T4/da active
- 2016-02-16 ES ES16710352T patent/ES2775498T5/es active Active
- 2016-02-16 BR BR112017014994-0A patent/BR112017014994B1/pt active IP Right Grant
- 2016-02-16 UA UAA201707110A patent/UA121874C2/uk unknown
- 2016-02-16 FI FIEP16710352.2T patent/FI3258919T4/fi active
- 2016-02-16 CR CR20170373A patent/CR20170373A/es unknown
- 2016-02-16 EP EP16710352.2A patent/EP3258919B2/en active Active
- 2016-02-16 KR KR1020177022473A patent/KR102121443B1/ko active Active
- 2016-02-16 AU AU2016220235A patent/AU2016220235B2/en active Active
- 2016-02-16 EP EP20151167.2A patent/EP3673899B1/en active Active
- 2016-02-16 LT LTEP16710352.2T patent/LT3258919T/lt unknown
- 2016-02-16 NZ NZ734035A patent/NZ734035A/en unknown
- 2016-02-16 HR HRP20200222TT patent/HRP20200222T4/hr unknown
- 2016-02-16 JP JP2017541993A patent/JP6522144B2/ja active Active
- 2016-02-16 MY MYPI2017702993A patent/MY175669A/en unknown
- 2016-02-16 PT PT167103522T patent/PT3258919T/pt unknown
- 2016-02-16 HU HUE16710352A patent/HUE049413T2/hu unknown
- 2016-02-16 PE PE2017001397A patent/PE20171334A1/es unknown
- 2016-02-16 EA EA201791560A patent/EA034820B1/ru unknown
-
2017
- 2017-07-02 IL IL253273A patent/IL253273B/en active IP Right Grant
- 2017-07-20 ZA ZA2017/04944A patent/ZA201704944B/en unknown
- 2017-07-31 DO DO2017000179A patent/DOP2017000179A/es unknown
- 2017-08-07 SA SA517382068A patent/SA517382068B1/ar unknown
- 2017-08-08 CL CL2017002031A patent/CL2017002031A1/es unknown
- 2017-08-11 CO CONC2017/0008148A patent/CO2017008148A2/es unknown
- 2017-08-14 SV SV2017005515A patent/SV2017005515A/es unknown
- 2017-08-16 PH PH12017501486A patent/PH12017501486A1/en unknown
- 2017-08-16 GT GT201700179A patent/GT201700179A/es unknown
- 2017-08-17 EC ECIEPI201753843A patent/ECSP17053843A/es unknown
-
2019
- 2019-02-04 US US16/266,640 patent/US12226456B2/en active Active
- 2019-02-27 ZA ZA2019/01241A patent/ZA201901241B/en unknown
- 2019-04-22 JP JP2019080836A patent/JP7094242B2/ja active Active
-
2020
- 2020-02-13 CY CY20201100132T patent/CY1122716T1/el unknown
-
2021
- 2021-04-13 JP JP2021067899A patent/JP7362687B2/ja active Active
- 2021-05-12 AU AU2021203035A patent/AU2021203035B2/en active Active
-
2023
- 2023-02-10 US US18/167,260 patent/US12370241B2/en active Active
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CL2017002031A1 (es) | Formulación en polvo nasal para el tratamiento de hipoglicemia | |
| CL2019000979A1 (es) | Composiciones y anticuerpos anti-lag-3. | |
| CL2016003075A1 (es) | Composición para tratar diabetes, que contiene un conjugado de análogo de insulina de acción prolongada y un conjugado de péptido insulinotrópico de acción prolongada | |
| CL2018002359A1 (es) | Métodos para usar agonistas de fxr | |
| CL2017003151A1 (es) | Formulaciones para vacunas contra la neoplasia y métodos para preparar las mismas | |
| CL2016002971A1 (es) | Combinación. | |
| MX373045B (es) | Inhibidores de mdm2 y metodos terapeuticos que utilizan el mismo. | |
| CR20170129A (es) | Uso de un agonista dual del receptor de glp-1/glucagón de acción prolongada para el tratamiento de la enfermedad del hígado graso no alcohólico | |
| MX378273B (es) | Compuestos activos hacia bromodominios. | |
| EA201790787A1 (ru) | Снижение вязкости фармацевтических составов | |
| MX372723B (es) | Métodos para marcar una molécula deuterada o no deuterada y formulaciones farmacéuticas para tratamiento. | |
| GB201411465D0 (en) | Active pharmaceutical ingredient (api) comprising cannabinoids for use in the treatment of cancer | |
| CL2018000688A1 (es) | Compuestos heterociclicos que contienen bencilamina y composiciones útiles contra infección por micobacterias | |
| CL2017001483A1 (es) | Formulación de relación fija de insulina glargina/lixisenatida | |
| MX2017007595A (es) | Inmunoterapia para enfermedad angiogenica. | |
| EA201791454A1 (ru) | Лекарственные формы для трансдермального введения | |
| CL2016002151A1 (es) | Derivados de piridazina para uso en la prevención o el tratamiento de un trastorno atáxico | |
| CR20180080A (es) | Combinaciones de un anticuerpo ox40 y un modulador de tlr4 y usos de las mismas | |
| CO2018011420A2 (es) | Formulaciones líquidas de fosfaplatino | |
| MA40642A (fr) | Nouveaux dérivés peptidiques et leurs utilisations | |
| MX2016009665A (es) | Composiciones y metodos para el tratamiento de la hemorragia cerebral. | |
| CL2016003271A1 (es) | Métodos para tratar infecciones | |
| NZ725354A (en) | Transdermal formulations of pergolide and uses thereof | |
| CL2019001046A1 (es) | Terapia de combinación que incluye un inhibidor mdm2 y uno o más agentes farmacéuticamente activos adicionales para el tratamiento de cáncer. (divisional solicitud 201601131) | |
| EA201301341A1 (ru) | Фармацевтическая композиция, обладающая панкреопротекторным действием, её применение для профилактики или лечения панкреатита и способ профилактики и лечения панкреатита |